DuPont Unveils Latest Silicone Blends Suitable for Topical Application

United States: DuPont de Nemours, Inc. has introduced innovative blends of Silicone elastomer and Silicone resin that cater to the growing need for skin care solutions among consumers. The formulations are specifically developed to comply with the ever-changing REACH regulatory standards and reflect DuPont's collaboration with its customers in pursuing the United Nations Sustainable Development Goals. In particular, the blends address UNSDG No. 3, which endeavours to promote and protect human health in all stages of life through the provision of safe skin care products.

The market is flooded with an increasing array of topical and medical products. These are now available sans prescription and are proving to be an effective remedy for various skin conditions like atopic dermatitis, psoriasis, scars, and actinic keratosis. DD has recently launched a product in response to public demand, which ensures that consumers can maintain healthy skin without compromising on drug effectiveness or protection. With the ever-evolving regulations surrounding over-the-counter healthcare products, the safety of such products for public usage and possible risks are minimized.

The company has recently launched two novel Silicone elastomer blends, namely Liveo TE-9320 Silicone Elastomer Blend and Liveo TE-9330 Silicone Elastomer Blend. In addition to these, the company is currently in the developmental phase of two more DuPont Silicone resin blends - Liveo TE-9720 Resin Blend and Liveo TE-9721 Resin Blend.

Liveo, a company that specializes in Silicone-based excipients, now offers a wide range of excipients that can help formulators create innovative solutions for delivering active pharmaceutical ingredients (APIs) in various topical forms, such as creams, sprays, ointments, lotions, gels or sticks. With the aid of Liveo's excipients, unique formulations can be developed, that are both visually appealing and effective in delivering drugs. This results in an improved user experience for patients, enhancing patient compliance with medication regimes. By simplifying application and increasing user comfort, these solutions help to ensure optimal drug delivery efficiency. Meanwhile, the share prices of Dupont have risen by 2.8% in the past year, outperforming its industry which saw a 2.7% decrease.

In its Q4 conference call, the company announced its net sales projection for the year 2023, which is expected to fall between $12,300 million to $12,900 million, with a forecasted adjusted earnings per share in the range of $3.50 to $4.00. For the first quarter of 2023, the company anticipates net sales of approximately $2,900 million, with estimated adjusted earnings per share of around 80 cents.

According to DuPont's forecast, the water and automotive adhesives sectors will maintain their robust performance, while the aerospace and healthcare industries will continue to see steady demand in 2023. Nevertheless, consumer electronics and semiconductor markets are likely to experience lower volumes during the first half of the year due to weakened consumer spending, inventory destocking, and COVID-19 related issues in China.

Additionally, the Water & Protection division may suffer from a downturn in the construction industry throughout 2023. Consequently, DuPont anticipates a mid-single-digit decline in organic sales in Q1 2023, reflecting persistent frailty in these consumer-oriented markets.